Intercept Pharmaceuticals (NAS:ICPT) Enterprise Value

: $393.4 Mil (As of Today)

View and export this data going back to 2012. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Intercept Pharmaceuticals's Enterprise Value is $393.4 Mil. Intercept Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-157.6 Mil. Therefore, Intercept Pharmaceuticals's EV-to-EBIT ratio for today is -2.50.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Intercept Pharmaceuticals's Enterprise Value is $393.4 Mil. Intercept Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-157.2 Mil. Therefore, Intercept Pharmaceuticals's EV-to-EBITDA ratio for today is -2.50.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Intercept Pharmaceuticals's Enterprise Value is $393.4 Mil. Intercept Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $294.5 Mil. Therefore, Intercept Pharmaceuticals's EV-to-Revenue ratio for today is 1.34.

Intercept Pharmaceuticals Enterprise Value Historical Data

The historical data trend for Intercept Pharmaceuticals's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Enterprise Value

2,927.94

3,966.29

921.33

604.88

360.75

Intercept Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Enterprise Value																813.39	720.59	419.23	360.75	459.30

Competitive Comparison

For the Biotechnology subindustry, Intercept Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Intercept Pharmaceuticals Enterprise Value Distribution

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Enterprise Value falls in comparison to its industry or sector. The grey bar indicates the Enterprise Value's extreme value range as defined by GuruFocus.

Intercept Pharmaceuticals Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Intercept Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

	Enterprise Value (A: Dec. 2022 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	513.643221	+	0	+	223.104
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	109.569	+	0	-	485.566
=	360.8

Intercept Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2023 is calculated as

	Enterprise Value (Q: Mar. 2023 )
=	Market Cap	+	Preferred Stock	+	Long-Term Debt & Capital Lease Obligation
=	559.857753	+	0	+	223.352
+	Short-Term Debt & Capital Lease Obligation	+	Minority Interest	-	Cash, Cash Equivalents, Marketable Securities
+	109.688	+	0	-	433.595
=	459.3

Intercept Pharmaceuticals (NAS:ICPT) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Intercept Pharmaceuticals's EV-to-EBIT for today is

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	393.437	/	-157.577
	=	-2.50

Intercept Pharmaceuticals's current Enterprise Value is $393.4 Mil.
Intercept Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.6 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Intercept Pharmaceuticals's EV-to-EBITDA for today is:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA(TTM)
	=	393.437	/	-157.237
	=	-2.50

Intercept Pharmaceuticals's current Enterprise Value is $393.4 Mil.
Intercept Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-157.2 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Intercept Pharmaceuticals's EV-to-Revenue for today is:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	393.437	/	294.522
	=	1.34

Intercept Pharmaceuticals's current Enterprise Value is $393.4 Mil.
Intercept Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $294.5 Mil.

Intercept Pharmaceuticals Enterprise Value Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (NAS:ICPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Enterprise Value

Comparable Companies

Traded in Other Exchanges

I4P:Germany

Address

10 Hudson Yards, 37th Floor, New York, NY, USA, 10001

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021
Luca Benatti	director	C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
Daniel Bradbury	director	BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Nancy Miller-rich	director	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451